AstraZeneca continues to redefine cancer treatment at the 2019 ASCO Annual Meeting
Data focused on breaking treatment boundaries, treating patients earlier in their disease, and raising the bar for better outcomes Presentations highlight Lynparza’s benefit in PARP-mediated cancers and Imfinzi’s three-year overall survival in unresectable, Stage III non-small cell lung cancerAstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines Lynparza (olaparib) and Imfinzi (durvalumab) at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 31 May to 4 June 2019.